One of the criticisms, which came from ASCO, points to the absence of consideration for patient heterogeneity that can result in physicians being penalized for providing patient-centered treatment.
CMS will experiment with moving cancer care into a value-based system with a new multi-payer payment and care delivery model. However, the model, developed by the Center for Medicare & Medicaid Innovation, is drawing criticism from stakeholders in oncology care, who say it could adversely impact optimal patient care by placing oncologists at risk for chemotherapy drugs.
“It builds on what we think is a broken fee-for-service system,” says Blase Polite, MD, chair of the American Society of Clinical Oncology (ASCO) Government Relations Committee and an oncologist at the University of Chicago. “It enshrines all the problems in fee-for-service, and it doesn’t give practices enough flexibility.”
Under the 5-year experimental Oncology Care Model (OCM), which will include nearly all cancers, participating practices will receive a care coordination fee totaling $160 for each 6-month period the patient is in chemotherapy. The fee comes on top of regular fee-for-service payments.
Complete story at AISHealth:
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More